[1] VERA C, RUEDA Z V. Transmission and colonization of Pneumocystis jirovecii[J]. J Fungi (Basel), 2021,7(11):979. [2] KUEHN H S, CHANG J, YAMASHITA M, et al. T and B cell abnormalities, Pneumocystis jirovecii pneumonia, and chronic lymphocytic leukemia associated with an AIOLOS defect in patients[J]. J Exp Med, 2021,218(12):e20211118. [3] LAI C C, SUN Y S, LIN F C, et al. Bronchoalveolar lavage fluid analysis and mortality risk in systemic lupus erythematosus patients with pneumonia and respiratory failure[J]. J Microbiol Immunol Infect, 2021,54(6):1048-1055. [4] LV X Y, XING W H, MA X, et al. Dynamic imaging changes of COVID-19 pneumonia at different stages[J]. Curr Med Imaging, 2022,18(8):869-875, [5] KUNIHIRO Y, TANAKA N, KAWANO R, et al. Differentiation of pulmonary complications with extensive ground-glass attenuation on high-resolution CT in immunocompromised patients[J]. Jpn J Radiol, 2021,39(9):868-876. [6] OBMANN V C, BICKEL F, HOSEK N, et al. Radiological CT patterns and distribution of invasive pulmonary Aspergillus, non-Aspergillus, Cryptococcus and Pneumocystis jirovecii mold infections-a multicenter study[J]. Rofo-Fortschr Rontg, 2021,193(11):1304-1314. [7] EGASHIRA R. High-resolution CT findings of myositis-related interstitial lung disease[J]. Medicine-Lithuania,2021,57(7):692. [8] GONG Y, GUAN L, JIN Z, et al. Effects of methylprednisolone use on viral genomic nucleic acid negative conversion and CT imaging lesion absorption in COVID-19 patients under 50 years old[J]. J Med Virol, 2020,92(11):2551-2555. [9] DU C J, LIU J Y, CHEN H, et al. Differences and similarities of high-resolution computed tomography features between Pneumocystis jirovecii pneumonia and cytomegalovirus pneumonia in AIDS patients[J]. Infect Dis Poverty, 2020,9(1):149. [10] MAERTENS J, CESARO S, MASCHMEYER G, et al. ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients[J]. J Antimicrob Chemoth,2016,71(9):2397-2404. [11] TANIGUCHI J, NAKASHIMA K, MATSUI H, et al. Low cut-off value of serum (1,3)-beta-D-glucan for the diagnosis of Pneumocystis jirovecii pneumonia in non-HIV patients: a retrospective cohort study[J]. BMC Infect Dis,2021,21(1):1200. [12] SCHMAJUK G, JAFRI K, EVANS M, et al. Pneumocystis jirovecii pneumonia (PJP) prophylaxis patterns among patients with rheumatic diseases receiving high-risk immunosuppressant drugs[J]. Semin Arthritis Rheu,2019,48(6):1087-1092. [13] PARK J W, CURTIS J R, MOON J, et al. Prophylactic effect of trimethoprim-sulfamethoxazole for Pneumocystis jirovecii pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids[J]. Ann Rheum Dis,2018,77(5):644-649. [14] PARK J W, CURTIS J R, JUN K I, et al. Primary prophylaxis for Pneumocystis jirovecii pneumonia in patients receiving rituximab[J]. Chest,2021:161(5):1201-1210. |